S

    SAB Biotherapeutics Inc (SABS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.71
    -0.08 (-2.11%)

    Market Cap: $344.84M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(8/20)
    Avg Surprise
    -58.08%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.27
    Range$-0.32 - $-0.22
    5 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.24+10.7%
    30d ago$-0.30-13.5%
    7d ago$-0.30-13.5%
    Current$-0.27
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    Dec 31, 2026
    EPS Consensus$-0.44
    Range$-0.62 - $-0.32
    5 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.44---
    Sep 26EST
    		-$-0.27---
    Jun 26
    		$-0.28$-0.29+3.45%Beat+74.3%
    Mar 26
    		$-0.35$-0.21-69.38%Miss+37.1%
    Dec 25
    		$-0.41$-0.17-141.18%Miss+58.2%
    Sep 25
    		$0.50$-0.46+208.70%Beat+144.6%
    Jun 25
    		$-1.09$-0.82-32.93%Miss-38.0%
    Mar 25
    		$-0.56$-1.07+47.66%Beat+50.9%
    Dec 24
    		$-0.98$-1.21+18.93%Beat+71.0%
    Sep 24
    		$-1.12$-1.09-2.75%Miss-10.9%
    Jun 24
    		$-0.79$-1.15+31.30%Beat+38.8%
    Mar 24
    		$-1.14$-0.98-16.33%Miss+23.0%
    Dec 23
    		$-3.38$-0.62-445.16%Miss-2012.5%
    Sep 23
    		$-1.01$-1.15+12.17%Beat+44.8%
    Jun 23
    		$-1.29$-1.45+11.03%Beat+14.0%
    Mar 23
    		$-1.48$-1.00-48.00%Miss-9.6%
    Dec 22
    		$-0.16$-0.16+0.00%Beat+75.8%
    Sep 22
    		$-1.83$-1.10-66.36%Miss-52.5%
    Jun 22
    		$-1.50$-1.00-50.00%Miss-4900.0%
    Mar 22
    		$-1.35$-1.10-22.73%Miss-260.7%
    Dec 21
    		$-0.66$-0.11-500.00%Miss-
    Sep 21
    		$-1.20$-0.60-100.00%Miss-
    Jun 21
    		$-0.03N/AN/ABeat-
    Mar 21
    		$0.84N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-6.84EV/EBITDA64.16x
    Price/FCF-5.15xFCF Yield-19.41%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-11.30%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage50.20x
    Current Ratio9.22xQuick Ratio9.22x
    Trading Statistics
    Beta0.53Avg Volume375.16K
    52-Week High$5.1552-Week Low$1.85

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.78
    SMA 20$3.79
    SMA 50$3.75
    SMA 200$3.81
    EMA 10$3.78
    EMA 20$3.76
    EMA 50$3.73
    EMA 200$3.55

    MACD

    Line: 0.03Signal: 0.03Hist: -0.00

    ADX

    ADX: 9.5+DI: 23.1-DI: 20.3

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down4.0
    PSAR$3.62

    Bollinger Bands

    Upper Band$3.93
    Lower Band$3.64
    %B Position775%(Upper)
    Band Width0.24

    RSI (14-Day)

    Neutral
    48.1

    Momentum Oscillators

    Stoch %K57.9
    Stoch %D71.0
    Williams %R-73.7
    ROC (10d)-1.6%
    Momentum-0.06
    CCI (20d)-72.5
    MFI (14d)52.5

    Volatility Measures

    ATR (14d)$0.16(4.3%)
    StdDev (20d)0.07
    Hist Vol37.9%(Moderate)

    Volume Flow

    VWAP$3.73
    OBV97.6M
    AD Line-86.8M
    CMF (20d)-0.060

    Volume Metrics

    Avg Vol (20d)360.1K
    Vol Ratio0.6x
    VWMA (20d)$3.79

    Pivot Points

    R3$4.13
    R2$4.06
    R1$3.92
    Pivot Point$3.85
    S1$3.72
    S2$3.65
    S3$3.52

    Advanced Oscillators

    TSI4.87
    Ultimate Osc50.4
    KST23.24

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$114,698$0$263,137$944,575$305,011$1.27M
    Cost of Revenue$0$0$763,299$0$0$0$785,713$0$0$0$944,401$0
    Gross Profit$0$0$-763,299$0$0$0$114,698$0$263,137$944,575$305,011$1.27M
    Operating Expenses$23.38M$20.00M$15.77M$12.68M$9.73M$10.77M$10.12M$11.31M$10.46M$12.34M$19.18M$6.59M
    R&D$16.17M$13.40M$10.73M$8.97M$7.00M$7.66M$7.45M$7.83M$6.82M$8.15M$4.30M$4.02M
    SG&A$7.21M$6.60M$5.04M$3.71M$2.73M$3.11M$2.67M$3.48M$3.64M$4.19M$14.88M$2.57M
    Operating Income$-23,377,000$-19,997,736$-15,770,231$-12,678,969$-9,732,000$-10,772,102$-10,008,840$-11,309,366$-10,201,698$-11,390,616$-18,873,771$-5,322,922
    Interest Income$1.71M$1.05M$700,739$655,233$14,000$62,498$136,374$277,174$374,557$497,893$484,046$14,364
    Interest Expense$62,000$62,745$63,462$43,292$64,000$69,565$70,875$78,036$93,119$76,371$77,879$69,700
    Income Before Tax$-22,491,000$-18,868,885$-16,860,743$45.45M$-10,114,000$-5,196,773$-11,394,699$-10,349,410$-7,335,455$-5,025,745$-22,856,763$-5,102,317
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-22,491,000$-18,868,885$-16,860,743$45.45M$-10,114,000$-5,196,773$-11,394,699$-10,349,410$-7,335,455$-5,025,745$-22,856,763$-5,102,317
    EBITDA$-23,313,745$-19,090,592$-16,771,585$45.58M$-9,270,812$-4,430,894$-10,693,829$-9,630,044$-6,647,016$-3,546,515$-22,318,529$-4,061,535
    EBIT$-24,138,000$-19,853,337$-17,498,020$44.83M$-10,064,000$-5,189,706$-11,460,198$-10,548,548$-7,616,893$-5,447,267$-23,262,930$-5,046,981
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SABS

    News

    Price to earnings forward of SAB Biotherapeutics, Inc. – BOATS:SABSW

    This article provides the "Price to earnings forward" value for SAB Biotherapeutics, Inc. (BOATS:SABSW). The data presented shows a "Period Value Change" but does not include specific numerical values. The content also lists various products, community features, and business solutions offered by TradingView.

    TradingView•8/21/26•
    Neutral

    Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics

    Woodline Partners LP has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,455,355 shares, or 6.8%, of SAB Biotherapeutics, Inc. common stock. This stake includes common shares and shares issuable from Series B Preferred Stock underlying Enrollment and Data Release Warrants. The percentage is based on 76,464,094 common shares outstanding as of May 6, 2026, with Woodline Partners holding sole voting and dispositive power over these shares.

    Stock Titan•8/15/26•
    Neutral

    Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund

    Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 7.3% in SAB Biotherapeutics (SABS). The Master Fund directly holds 6,627,501 shares, representing this percentage based on 90,986,368 shares outstanding as of August 3, 2026. All reporting persons have shared voting and shared dispositive power over these shares, with no sole voting or dispositive power.

    Stock Titan•8/14/26•
    Neutral

    Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G

    Caligan Partners LP and David Johnson have filed an amended Schedule 13G, disclosing beneficial ownership of 7,967,207 shares of SAB Biotherapeutics, Inc. (SABS) common stock, representing an 8.8% stake. This ownership is based on 90,986,368 shares outstanding as of August 3, 2026. Both Caligan Partners, as an investment manager, and David Johnson, as its managing partner, hold shared voting and dispositive power over these shares, indicating a passive investment purpose.

    Stock Titan•8/14/26•
    Neutral

    Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants

    Vivo funds have disclosed beneficial ownership of 9.99% stakes in SAB Biotherapeutics (SABS) through various entities, including Vivo Opportunity Fund Holdings and Vivo Opportunity Cayman Fund. These stakes comprise common stock, Series B Preferred Stock, and warrants, with built-in blocking provisions ensuring that ownership does not exceed 9.99% of the issuer's voting securities upon conversion or exercise. The filing details the specific share counts and types of securities held by each fund.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About SABS

    Does SABS pay dividends?
    SAB Biotherapeutics Inc (SABS) does not currently pay a regular dividend.
    What is SABS's market cap?
    SAB Biotherapeutics Inc (SABS) has a market capitalization of $344.84M with a current stock price of $3.71.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In